Evidence map›Paper›PMID 42515114›Full record

ReviewToxics2026

Mechanistic Evidence Mapping Ochratoxin A Toxicity onto Alzheimer's Disease-Relevant Neurodegenerative Pathways: A Systematic Review of Experimental Models.

Raquel Penalva-Olcina, Felipe Franco-Campos, Mercedes Taroncher, María-José Ruiz, Mónica Fernández-Franzón

Abstract readReview
In one paragraph

Review in Toxics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Raquel Penalva-OlcinaToxicology and Food Chemistry Laboratory, Faculty of Pharmacy and Food Science, Universitat de València, Av. Vicent Andrés Estellés 22, 46100 Burjassot, Spain.
Felipe Franco-CamposToxicology and Food Chemistry Laboratory, Faculty of Pharmacy and Food Science, Universitat de València, Av. Vicent Andrés Estellés 22, 46100 Burjassot, Spain.ORCID 0009-0002-7850-6186
Mercedes TaroncherToxicology and Food Chemistry Laboratory, Faculty of Pharmacy and Food Science, Universitat de València, Av. Vicent Andrés Estellés 22, 46100 Burjassot, Spain.ORCID 0000-0002-8752-0951
María-José RuizToxicology and Food Chemistry Laboratory, Faculty of Pharmacy and Food Science, Universitat de València, Av. Vicent Andrés Estellés 22, 46100 Burjassot, Spain.ORCID 0000-0003-4174-6688
Mónica Fernández-FranzónToxicology and Food Chemistry Laboratory, Faculty of Pharmacy and Food Science, Universitat de València, Av. Vicent Andrés Estellés 22, 46100 Burjassot, Spain.

Funding

Ministry of Science and Information PID2024-160527OB-I00
6 · The paper itself

Abstract

Ochratoxin A (OTA) is a prevalent foodborne mycotoxin that has been increasingly recognized as a potential environmental contributor to neurodegenerative diseases. Despite extensive research, a systematic integration of how OTA replicates the specific pathological hallmarks of Alzheimer's Disease (AD) is currently lacking. This study provides a comprehensive systematic review of the mechanistic evidence linking OTA exposure to AD-related pathways, utilizing the Adverse Outcome Pathway (AOP) framework to categorize complex toxicological data into biological key events (KEs). A systematic literature search was conducted across PubMed, Scopus, and Web of Science. A total of 24 peer-reviewed articles were selected for synthesis, comprising 14 in vitro studies and 10 in vivo investigations. The integrated evidence demonstrates that OTA exposure triggers a robust toxicological cascade that replicates several key mechanistic pathways associated with AD in experimental models. Early molecular triggers involve significant redox imbalance and mitochondrial bioenergetic failure, which serve as catalysts for sustained neuroinflammation and microglial activation. In vivo data, from multiple animal models, consistently show that these cellular dysfunctions culminate in structural damage. This systematic integration provides a clearer roadmap for future risk assessment and emphasizes the urgent need for refined regulatory guidelines to protect neurological health from chronic mycotoxin exposure.

Indexed as

Alzheimer’s disease (AD)blood–brain barrier (BBB)neurodegenerative diseasesneuroinflammationneurotoxicityochratoxin A (OTA)

Identifiers

PMID42515114
PMCPMC13418596

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.